Trial Profile

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Orally-administered Replication-competent Adenovirus Type-4 HIV Vaccine Regimens in Combination With an AIDSVAX B/E Boost in Healthy, HIV-uninfected Adult Participants

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 20 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad4-EnvC150 (Primary) ; Ad4-mGag (Primary) ; HIV gp120 vaccine (Primary) ; Aluminium hydroxide
Indications HIV infections
Focus Adverse reactions
Sponsors Emergent BioSolutions; PaxVax

15 Mar 2024 Status changed from active, no longer recruiting to discontinued.
03 Jul 2018 Planned End Date changed from 1 Feb 2017 to 1 Feb 2019.
17 May 2016 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com